University of Illinois at Chicago
Chicago, Illinois, 60612, United States
NCT Number: NCT05114798
Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.
This study is active but is not currently recruiting participants.
Notify Me45 year–70 year
All sexes
Interventional
Not applicable
Chicago, Illinois, 60612, United States
Approximately 42% of the U.S. adult population is obese and data suggests that persons with obesity are at a 30% greater risk of developing colorectal cancer (CRC). Therefore, efficacious approaches to preventing and treating obesity will have significant effects on CRC incidence in the U.S. Although calorie restriction through lifestyle intervention is the most common approach to treat obesity, clinically meaningful weight loss is difficult to achieve via this method due to low adherence with calorie monitoring, indicating a need for innovation. Time-restricted eating, a type of intermittent fasting, has been shown in animals to impart cancer protective effects including lower body weight, decreased systemic inflammation, and improved glucose metabolism. Time-restricted eating is where individuals are asked to consume all their food for the day within a specified time frame, and water fast for the remaining hours of the day. We recently performed two short-term (≤12-weeks) pilot studies of time-restricted eating to evaluate its safety and preliminary efficacy on body weight and chronic disease risk markers in adults with obesity. Our results show the intervention is a safe and acceptable approach to weight loss among obese adults. Moreover, time-restricted eating produced approximately 3% weight loss from baseline and reductions in systolic blood pressure, oxidative stress and insulin resistance. Although these pilot findings show promise for time-restricted eating as an effective tool for CRC risk reduction among obese individuals, these data still require confirmation by a well powered longer-term clinical trial. The present proposal aims to implement a 12-month (6-month intervention, 6-month maintenance) controlled, parallel arm trial among 255 obese adults (45-70 years old) who have had a colonoscopy. Subjects will be randomized to 1 of 3 groups: 1) 8-hour time-restricted eating (daily ad libitum food intake from 12pm - 8pm), 2) Calorie restriction (daily 25% calorie restriction), or 3) Control (daily ad libitum food intake, no meal timing restrictions) to compare the effects on: (1) Body weight, body composition, and intervention adherence; (2) Circulating metabolic, inflammation, and oxidative stress-related biomarkers; (3) Colonic mucosal gene expression profiles and mucosal inflammation, DNA damage and cellular growth; and (4) maintenance of benefits on body weight/composition and CRC markers.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
Time frame: Baseline to month 6
Body weight in kg
Time frame: Baseline, 6 month and 12 month
Total and regional body fat composition and distribution will be measured via whole body DEXA scan
Time frame: Monthly, through month 6
Measured through electronic diet records and 24 hour dietary recalls
Time frame: Baseline, month 3, month 6, month 9, month 12
From fasting venous blood measured by a commercial lab
Time frame: Baseline, month 3, month 6, month 9, month 12
Multiplex ELISA
Time frame: Baseline, month 3, month 6, month 9, month 12
ELISA
Time frame: Baseline, month 6, month 12
Commercially available targeted transcriptomics platform
Time frame: Baseline, month 6, month 12
Healthy colonic mucosa, immunohistochemistry
Time frame: Baseline, month 6, month 12
Healthy colonic mucosa, immunohistochemistry,
Time frame: Baseline, month 6, month 12
Healthy colonic mucosa, immunohistochemistry
Time frame: Month 6 to month 12
Maintenance of weight loss
Time frame: Baseline, month 3, month 6, month 9, month 12
From fasting venous blood measured at a commercial lab
Time frame: Baseline, month 3, month 6, month 9, month 12
calculated from fasting glucose and insulin using a standard formula
Time frame: Baseline, month 3 and month 6
Shotgun metagenomics
Time frame: Baseline, month 3 and month 6
Untargeted Metabolomics
Time frame: Baseline, month 3, month 6
Untargeted Metabolomics
University of Illinois at Chicago
Other
Effects of Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers Among Adults With Obesity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06501001
Behavior, Body Weight
Toledo, Spain
View Trial DetailsNCT06891352
Behavior, Body Weight
La Jolla, California, United States
View Trial DetailsNCT06323889
Behavior, Body Weight
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT06018415
Behavior, Body Weight
Xi'an, Shaanxi, China
View Trial Details